BridgeBio Pharma, Inc. (BBIO)
NasdaqGS
Price as at 10 Aug 2026, 23:01 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
BridgeBio Pharma, Inc. trades at USD84.67. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
15 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Farallon Capital, FARALLON CAPITAL MANAGEMENT, L.L.C.$800.14M · 3.7% of book
- Andreas Halvorsen, VIKING GLOBAL INVESTORS LP$741.02M · 2.1% of book
- Two Sigma, TWO SIGMA INVESTMENTS, LP$351.71M · 0.3% of book
- Ken Griffin, CITADEL ADVISORS LLC$280.05M · 0.0% of book
- D. E. Shaw, D. E. Shaw & Co., Inc.$270.59M · 0.1% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Which funds own BBIO?
15 of the institutions we track reported a position in BBIO in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its BBIO data?
Fundamentals for BBIO come from company filings and exchange data, as listed on NasdaqGS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 10 Aug 2026, 23:01 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for BBIO, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.